Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer.

Abstract

Colorectal cancer remains a major cause of mortality in the USA, despite advances in prevention and screening. Existing therapies focus primarily on generic treatment such as surgical intervention and chemotherapy, depending on disease severity. As personalized medicine and targeted molecular oncology continue to develop as promising treatment avenues, there has emerged a need for effective targets and biomarkers of colorectal cancer. The transmembrane receptor guanylyl cyclase C (GUCY2C) regulates intestinal homeostasis and has emerged as a tumor suppressor. Further, it is universally expressed in advanced metastatic colorectal tumors, as well as other cancer types that arise through intestinal metaplasia. In this context, GUCY2C satisfies many characteristics of a compelling target and biomarker for gastrointestinal malignancies.

• Authors: Adi Caspi, Ariana A Entezari, Madison Crutcher, Adam E Snook, Scott A Waldman
• Journal: Personalized medicine (Per Med) Vol. 19 Issue 5 Pg. 457-472 (09 2022) ISSN: 1744-828X [Electronic] England
• PMID: 35920071 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• GUCY2C protein, human
• Receptors, Enterotoxin

Topics

• Colorectal Neoplasms (diagnosis, drug therapy, genetics)
• Humans
• Receptors, Enterotoxin